Concord Biotech Ltd
Concord Biotech Ltd (CONCORDBIO) last reported results for the quarter ended Jun 2026, with sales of ₹257 crore and net profit of ₹58 crore. The next scheduled event is a bonus issue on 24 Oct 2026. The stock last traded at ₹1,363, a market capitalisation of ₹14,264 crore, on a P/E of 51.4. Over the past 52 weeks the stock has ranged between ₹987 and ₹1,648. Figures are as of 6 Oct 2026 and are not real time.
Concord Biotech Ltd share price and key metrics
- Current price
- ₹1,363
- Market cap
- ₹14,264 cr
- Stock P/E
- 51.4
- Book value
- ₹193
- ROE
- 12.5%
- ROCE
- 17.1%
- Dividend yield
- 0.56%
- 52w high / low
- 1648/987
Metrics as of 6 Oct 2026. Not real time.
Track Concord Biotech Ltd
Cruxal reads every Concord Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Concord Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 7%
- TTM
- -7%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- 0%
- TTM
- -22%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 7%
- 1 Year
- -16%
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 18%
- Last Year
- 12%
Concord Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹257 cr, up 26.0% from ₹204 cr a year earlier. Net profit was ₹58 cr, up 31.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Operating profit | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 43% | 40% | 44% | 30% | 36% | 35% | 36% | 32% |
| Other income | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax % | 27% | 25% | 24% | 25% | 26% | 26% | 22% | 26% |
| Net profit | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS (₹) | 9.15 | 7.26 | 13.42 | 4.21 | 6.08 | 6.16 | 8.49 | 5.59 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Concord Biotech Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Operating profit | 205 | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 40% | 53% | 38% | 40% | 42% | 42% | 35% | 35% |
| Net profit | 169 | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS (₹) | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 | 26.32 |
TTM is the trailing twelve months to the most recent quarter.
Concord Biotech Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 | 2,007 |
| Borrowings | 52 | 86 | 62 | 32 | 10 | 3 | 2 |
| Other liabilities | 118 | 97 | 147 | 192 | 164 | 219 | 212 |
| Total liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 |
| Fixed assets | 240 | 546 | 573 | 593 | 575 | 795 | 789 |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 | 79 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 | 491 |
| Other assets | 361 | 477 | 592 | 611 | 668 | 854 | 873 |
| Total assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 | 2,232 |
As reported by the company. Total assets equal total liabilities by construction.
Concord Biotech Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 155 | 167 | 207 | 246 | 265 | 245 | 267 |
| Cash from investing | -114 | -195 | -112 | -158 | -155 | -160 | -143 |
| Cash from financing | -43 | 31 | -100 | -85 | -99 | -99 | -113 |
| Net cash flow | -1 | 3 | -4 | 3 | 12 | -14 | 11 |
| Free cash flow | -1 | -38 | 52 | 101 | 180 | 134 | 172 |
| CFO / operating profit | 100% | 74% | 99% | 92% | 85% | 70% | 100% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Concord Biotech Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 32% | 21% | 26% | 28% | 28% | 17% |
| Debtor days | 131 | 105 | 119 | 117 | 125 | 159 | 159 |
| Inventory days | 312 | 503 | 434 | 430 | 331 | 286 | 485 |
| Days payable | 201 | 152 | 185 | 190 | 150 | 135 | 151 |
| Cash conversion cycle | 242 | 456 | 368 | 357 | 306 | 310 | 493 |
| Working capital days | 159 | 177 | 161 | 152 | 166 | 193 | 230 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Concord Biotech Ltd shareholding pattern
Promoters held 44.08% at Jun 2026, broadly unchanged since Jun 2025. FIIs 7.53% and DIIs 9.37%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FIIs | 8.10% | 8.33% | 9.35% | 9.10% | 8.03% | 7.58% | 7.79% | 7.53% |
| DIIs | 9.89% | 9.65% | 9.16% | 8.85% | 9.55% | 9.58% | 9.22% | 9.37% |
| Public | 37.95% | 37.93% | 37.41% | 37.94% | 38.32% | 38.75% | 38.90% | 39.04% |
| No. of shareholders | 84,298 | 82,004 | 81,219 | 82,045 | 82,650 | 81,815 | 82,249 | 83,325 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Concord Biotech Ltd events
The next scheduled event is a bonus issue on 24 Oct 2026.
- Bonus issueApproval for 1:1 bonus issue and increase in authorized share capital
- Corporate eventPostal Ballot for special business
See the full results calendar for every Indian company reporting in the next 30 days.
Cruxal coverage of Concord Biotech Ltd
Concord Biotech Ltd corporate filings
- In compliance with regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we furnish herewith certificate received from RTA of the Company.Company Updatelow impact
- Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and as per the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading ....Insider Trading / SASTlow impact
- Concord Biotech Ltd publishes notice for Postal Ballot and remote e-votingCompany Updatelow impact
Cruxal's analysis: Concord Biotech has issued a newspaper advertisement regarding the Notice of Postal…
Read the full analysis - Concord Biotech Limited Announces 1:1 Bonus Issue and Increase in Authorized Share CapitalAGM/EGMhigh impact
Cruxal's analysis: Concord Biotech Limited has announced a 1:1 bonus equity share issue, proposing to…
Read the full analysis - Concord Biotech Limited Announces 1:1 Bonus Issue and Increase in Authorized Share CapitalBoard Meetingmedium impact
Cruxal's analysis: Concord Biotech Limited has approved a 1:1 bonus issue, granting one new equity share for…
Read the full analysis - Concord Biotech Limited schedules board meeting to consider bonus equity share issuanceBoard Meetingmedium impact
Cruxal's analysis: Concord Biotech Limited has announced a board meeting scheduled for September 23, 2026…
Read the full analysis - Concord Biotech reports outcome of USFDA inspection at Unit II Valthera facilityCompany Updatelow impact
Cruxal's analysis: Concord Biotech has provided an intimation regarding the outcome of a USFDA inspection…
Read the full analysis - Concord Biotech schedules analyst and investor meeting for September 23, 2026Company Updatelow impact
Cruxal's analysis: Concord Biotech has announced a scheduled meeting with analysts and investors to take…
Read the full analysis - Concord Biotech to attend investor conference on August 26, 2026Company Updatelow impact
Cruxal's analysis: Concord Biotech has announced that company officials will participate in an investor…
Read the full analysis - Concord Biotech Reports Strong Q1 FY27 Performance with 26% YoY Revenue Growth and 31% PAT GrowthCompany Updatehigh impact
Cruxal's analysis: Concord Biotech Limited reported a robust start to FY27 with Q1 revenue of INR257 crore…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.